S&P 500   3,008.66 (+0.06%)
DOW   26,855.65 (+0.10%)
QQQ   192.93 (-0.24%)
AAPL   241.42 (+0.38%)
FB   184.51 (-2.77%)
GOOGL   1,243.53 (-0.06%)
AMZN   1,772.79 (-0.72%)
MU   45.32 (+0.20%)
TSLA   254.94 (+0.57%)
T   38.28 (+0.13%)
ACB   3.58 (-2.98%)
NFLX   268.06 (-3.59%)
BAC   31.28 (+0.81%)
DIS   132.58 (+1.78%)
S&P 500   3,008.66 (+0.06%)
DOW   26,855.65 (+0.10%)
QQQ   192.93 (-0.24%)
AAPL   241.42 (+0.38%)
FB   184.51 (-2.77%)
GOOGL   1,243.53 (-0.06%)
AMZN   1,772.79 (-0.72%)
MU   45.32 (+0.20%)
TSLA   254.94 (+0.57%)
T   38.28 (+0.13%)
ACB   3.58 (-2.98%)
NFLX   268.06 (-3.59%)
BAC   31.28 (+0.81%)
DIS   132.58 (+1.78%)
Log in

Y-mAbs Therapeutics Stock Price, News & Analysis (NASDAQ:YMAB)

$28.49
+0.31 (+1.10 %)
(As of 10/22/2019 12:02 PM ET)
Today's Range
$28.49
Now: $28.49
$29.07
50-Day Range
$23.91
MA: $27.37
$31.80
52-Week Range
$15.17
Now: $28.49
$32.27
Volume3,241 shs
Average Volume120,689 shs
Market Capitalization$985.47 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.11 per share

Profitability

Net Income$-43,270,000.00

Miscellaneous

Employees32
Market Cap$985.47 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.


Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) issued its earnings results on Wednesday, August, 14th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.05. View Y-mAbs Therapeutics' Earnings History.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Y-mAbs Therapeutics.

What price target have analysts set for YMAB?

3 analysts have issued twelve-month price targets for Y-mAbs Therapeutics' shares. Their predictions range from $38.00 to $40.00. On average, they anticipate Y-mAbs Therapeutics' share price to reach $39.00 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

What is the consensus analysts' recommendation for Y-mAbs Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

Has Y-mAbs Therapeutics been receiving favorable news coverage?

News stories about YMAB stock have been trending very positive this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a news impact score of 4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Y-mAbs Therapeutics.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 841,300 shares, an increase of 10.1% from the August 30th total of 764,000 shares. Based on an average trading volume of 175,200 shares, the days-to-cover ratio is currently 4.8 days. Approximately 6.0% of the company's stock are short sold. View Y-mAbs Therapeutics' Current Options Chain.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the folowing people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
  • Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Strs Ohio (0.06%) and Tuttle Tactical Management (0.03%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio and Tuttle Tactical Management. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $28.49.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $985.47 million. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]


MarketBeat Community Rating for Y-mAbs Therapeutics (NASDAQ YMAB)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote "Outperform" if you believe YMAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel